

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

CD3 Monoclonal Antibody (OKT3), eBioscience

RRID:AB_467057

Type: Antibody

Proper Citation

Thermo Fisher Scientific Cat# 14-0037-82, RRID:AB_467057

Antibody Information

URL: http://antibodyregistry.org/AB_467057

Proper Citation: Thermo Fisher Scientific Cat# 14-0037-82, RRID:AB_467057

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow, ICC/IF
Consolidation on 1/2020: AB_467057, AB_10114114

Antibody Name: CD3 Monoclonal Antibody (OKT3), eBioscience

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_467057

Vendor: Thermo Fisher Scientific

Catalog Number: 14-0037-82

Record Creation Time: 20250819T233307+0000

Record Last Update: 20250820T054105+0000

Ratings and Alerts

No rating or validation information has been found for CD3 Monoclonal Antibody (OKT3), eBioscience.

No alerts have been found for CD3 Monoclonal Antibody (OKT3), eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Xiang H, et al. (2026) Predominant mutated non-canonical tumor-specific antigens identified by proteogenomics demonstrate immunogenicity and tumor suppression in CRC. *Cell genomics*, 6(1), 101062.

Chi H, et al. (2025) SEMA3G-NRP1 Signaling Functions as an Immune Checkpoint That Enables Tumor Immune Evasion by Impairing T-cell Cytotoxicity. *Cancer research*, 85(5), 912.

Kim AR, et al. (2025) Co-blockade of TGF β and PD-1 Reinvigorates Glioblastoma-Infiltrating CD8 $^{+}$ T Cells That Characteristically Upregulate TGF β RI Expression. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3306.

Yang H, et al. (2025) FAM49B mediates tumor progression and poor prognosis of gastric cancer through activating PI3K/AKT pathway. *Journal of molecular histology*, 56(5), 291.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. *Cell reports. Medicine*, 6(3), 101977.

Landi D, et al. (2025) A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. *Cancer research communications*, 5(3), 527.

Pi R, et al. (2025) NKp30 and NKG2D contribute to natural killer cell-mediated recognition of HIV-infected cells. *iScience*, 28(10), 113548.

Deka A, et al. (2024) Non-canonical NF- κ B signaling limits the tolerogenic β -catenin-Raldh2 axis in gut dendritic cells to exacerbate intestinal pathologies. *The EMBO journal*, 43(18), 3895.

Zhang J, et al. (2024) Osr2 functions as a biomechanical checkpoint to aggravate CD8 $^{+}$ T cell exhaustion in tumor. *Cell*, 187(13), 3409.

De Sanctis F, et al. (2024) Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer.

Immunity, 57(6), 1378.

Lai TJ, et al. (2024) Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma. *Cancer research communications*, 4(7), 1834.

Sanna FC, et al. (2024) IL-2 and TCR stimulation induce expression and secretion of IL-32 ? by human T cells. *Frontiers in immunology*, 15, 1437224.

Wang Y, et al. (2024) Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. *Cell reports. Medicine*, 5(1), 101374.

Abdelfattah NS, et al. (2024) T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics. *Immunity*, 57(12), 2945.

Guan X, et al. (2024) Immunogenic peptides putatively from intratumor microbes: Opportunities for colorectal cancer treatment. *iScience*, 27(12), 111338.

Sievers C, et al. (2023) Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. *Cancer cell*, 41(5), 887.

Dezfulian MH, et al. (2023) TScan-II: A genome-scale platform for the de novo identification of CD4+ T cell epitopes. *Cell*, 186(25), 5569.

Worboys JD, et al. (2023) TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. *Nature communications*, 14(1), 5016.

Johari M, et al. (2022) Comprehensive transcriptomic analysis shows disturbed calcium homeostasis and deregulation of T lymphocyte apoptosis in inclusion body myositis. *Journal of neurology*, 269(8), 4161.

Buonato JM, et al. (2022) Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain. *Molecular cancer therapeutics*, 21(7), 1171.